Overview
HROW market data
Price History
HROW price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.14 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.14 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -13.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $28.54 – $54.85 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.5B · P/B 34.60 · P/S 5.27.
Company News
BTIG Reiterates Buy on Harrow, Maintains $63 Price TargetBenzinga · Aug 11, 2026, 6:03 PM
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Aug 11, 2026, 12:04 PM
8-K filing — HARROW, INC. (HROW)SEC EDGAR · Aug 10, 2026, 8:10 PM
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M EstBenzinga · Aug 10, 2026, 8:09 PM
Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M EstimateBenzinga · Aug 10, 2026, 8:08 PM
Viatris Sharpens Focus with Divestiture, Hikes 2026 OutlookBenzinga · Aug 6, 2026, 5:56 PM
Harrow Announces Agreement To Acquire Dry Eye Nasal Spray TYRVAYA From Viatris For $30M Cash At Closing, Up To $70M In Sales MilestonesBenzinga · Aug 6, 2026, 11:22 AM
Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To LucentisBenzinga · Jul 20, 2026, 12:04 PM
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingGlobenewswire Inc · Jul 20, 2026, 12:02 PM
Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual MeetingBenzinga · Jul 20, 2026, 11:20 AM